The short answer is, “no;” not all children with autism will benefit from leucovorin because one-size-fits-all-medicine doesn’t fit all sizes, especially in the pediatric population. The best therapeutics work best and have more sustainable benefits when given in the right context, under the right circumstances, with the least harm. With leucovorin it is no different. However, some children with autism have already experienced significant benefits from this prescription form of vitamin B9, with dramatic improvements in language and communication skills or behavioral symptoms.
What Is Leucovorin?
To better understand the potential value of leucovorin, it is important to understand how folate, the natural and most useful form of vitamin B9 is used in and by the body. The active form of vitamin B9, methylfolate, is an essential component of cell division, DNA synthesis, and neurodevelopment; it plays a major role in our brains! A body that is lacking access to adequate methylfolate can be at a huge disadvantage, especially if B9 is low or inaccessible in utero and during a child’s early development.
Not all B vitamins are created equally, nor are different forms of B vitamins utilized by different bodies equally. Some people have difficulty converting the natural form of folate into the active, methylated form, and they may need to take supplements. This can be true for vitamins B12 and B6 as well. Our brains usually rely on one of three pathways to get access to methylfolate from our diets or supplementation. Folinic acid, a lesser utilized precursor to methylfolate, can be used by the body when the two main pathways are blocked. It is kind of the “alternative, less efficient path, used in a pinch” version of vitamin B9 that allows the brain to bypass some situations that block our main access pathways to folate in our brains.
You may already know that for many decades, healthcare providers have emphasized the importance of a pregnant mother getting enough folate in her diet to avoid a neural tube defect in her child, one called spina bifida. Given the important role folate plays in healthy development, and the number of children suffering from severe neurologic symptoms today, it is not a stretch to imagine how poor access to folate might be involved, or how improving access to usable forms of folate might help alleviate symptoms or improve neurologic function and development conditions in children with autism who lack access.
Folate Levels Are Bio-Individual
Each child’s need for folate is bio-individual and usually a matter of their total load – a broad combination of adverse factors (and helpful supports) contributing to their health at a given time. For instance, poor methylation (due to one’s genetics), low vitamin D, inappropriate levels of homocysteine or low glutathione in the blood can all contribute to a body’s inefficient use of folate. Additionally, chronic infections, certain dietary habits, and too much synthetic folic acid, if not eliminated, can impact a child’s access to folate.
You may have thought, as most of us in medicine have been taught, that the right thing to use as a preventative measure is “folic acid” which sounds similar but is NOT folate. Folic acid is a synthetic form of B9 found in many fortified foods and vitamins (including prenatal vitamins) that does not work as folate. When present in high enough amounts, folic acid actually blocks a brain’s access to folate through something called competitive inhibition – it takes up the folate-receptor binding sites (binding much tighter than active folate can) so that folate is essentially blocked. Unfortunately, the recommended medical approach has not been updated to inform the public that this is so, and major medical institutions still recommend and encourage the use of folic acid, when methylfolate is what is needed.
What Is the Historical Use of Leucovorin?
Leucovorin, also known as folinic acid, is a medically recognized form of folate (vitamin B9) used in various clinical conditions to enhance folate activity where it might be impaired. Leucovorin bypasses the main pathways the body uses to access folate compounds; it uses the less efficient, “in-a-pinch pathway”. This makes it particularly valuable in situations where folate metabolism is compromised, such as in cases involving specific genetic mutations or autoimmune activity. Leucovorin’s ability to circumvent standard metabolic blockades is what makes it stand out therapeutically.
Historically, leucovorin was introduced in cancer treatment regimens, especially to “rescue” healthy cells from the toxic effects of methotrexate, a chemotherapy agent. Its role has since expanded to other conditions, including certain types of anemia, and, more recently, has garnered attention for its potential benefits in individuals with neurodevelopmental challenges, particularly those with autism spectrum disorder (ASD).
Folate-Receptor Antibodies in Autism
Folate-receptor antibodies (FRAs) are immune proteins that “mistakenly” target and block folate receptors on cells. These receptors are critical for transporting folate into the brain and across various tissues. When FRAs are present, they can impede this process, leading to what’s known as “cerebral folate deficiency.”
Many children with autism have elevated levels of folate-receptor antibodies in their blood, which prevents normal folate transport to the brain. This shortage of folate in the central nervous system can contribute to a range of neurological and behavioral symptoms, some of which overlap with those seen in autism spectrum disorder.
Medical research (see Sources & References, below) has demonstrated a much higher prevalence of these antibodies among children with autism compared to neurotypical children. Some studies indicate that up to 60%-75% of autistic children may test positive for FRAs.
The presence of FRAs is not necessarily exclusive to autism, but their effect appears especially profound in this group. When folate can’t cross into the brain efficiently during early development, it can disrupt a variety of processes important for speech, cognition, and social interaction.
Clinically, testing for FRAs involves blood work and is typically considered when children present with both autism symptoms and signs suggestive of folate problems—such as developmental regression, movement abnormalities, or unresponsiveness to standard interventions.
How Can Leucovorin Help with Folate-Receptor Antibodies?
Synthetic folic acid and natural forms of folate supplementation are often ineffective in children with folate-receptor antibodies because the blocked receptor prevents the vitamin from reaching its target. The use of leucovorin can often bypass the blocked receptors. It can cross into the brain through the alternate, less vulnerable pathway, alleviating the deficiency caused by folate-receptor antibodies and thereby convert to the methylated form of folate. Some children treated with leucovorin show marked improvements in cognitive and behavioral symptoms tied to cerebral folate deficiency.
Why Is Leucovorin Helpful for Some Children with Autism but Not for Others?
One of the intriguing aspects of leucovorin therapy is its selective impact on children with autism. Not every child benefits, and the underlying reason often centers around folate-receptor antibodies. Autism is a heterogeneous disorder, with numerous causes and manifestations, but a substantial subset of children with autism exhibit elevated levels of FRAs.
As mentioned previously, up to 60-75% of children with autism may have folate-receptor antibodies, but the remaining group does not. Outside this group, leucovorin supplementation typically doesn’t result in significant changes, as their folate metabolism and absorption remain intact. In other words, leucovorin is not a panacea for autism, but a targeted intervention for a known biological subgroup.
Furthermore, the amount of leucovorin needed (or other forms of folate required) and long-term effectiveness of treatment gets back to total load and what else a child’s body is struggling with – other vitamin deficiencies like low vitamin D? Toxins? Infections? A child’s capacity to handle oxidative stress or access glutathione – the body’s major antioxidant? By addressing a child’s total load and other root causes of folate deficiency, the amount of other medications could be eliminated or dramatically lowered, including leucovorin.
Can Leucovorin Be Harmful to Children with Autism?
As with any medication, potential risks and side effects must be considered. Leucovorin is generally safe and well-tolerated, especially when used according to established protocols. Most adverse effects are mild, such as gastrointestinal upset or minor allergic reactions. However, rare but important risks do exist, especially when other root causes of low folate are not also taken into consideration or addressed along with this therapy.
Overstimulation is the most frequently described concern among children with autism who take leucovorin. Parents and clinicians have occasionally observed increased hyperactivity, sleep disturbances, or agitation after starting leucovorin, especially at higher doses. The mechanism isn’t fully understood, but it may relate to the rapid influx of activated folate into neurological pathways, which can trigger an exaggerated response in susceptible individuals.
Additionally, leucovorin may interfere with certain seizure medications or alter neurotransmitter balances, necessitating careful medical supervision during its use. Monitoring and dose adjustments typically resolve any issues. Importantly, serious events are rare, and the overall safety profile is favorable compared to many neuropsychiatric medications. The decision to use leucovorin should always be made collaboratively between families and healthcare providers, weighing the potential benefits against the specific risks for each child.
Is Leucovorin a Cure for Autism?
While leucovorin has garnered significant attention for sometimes dramatic improvements in children with autism, it’s important to emphasize that it is not a cure for autism. Autism is a multifaceted developmental disorder, influenced by genetics, environmental factors, and other total-load root causes. Any intervention, including leucovorin, should be understood as a tool to address certain symptoms or underlying biological dysfunctions rather than to “reverse” the condition entirely. There is no therapy or intervention or medication that’s going to work for every child. Because autism is multifactorial and bio-individual, interventions are also going to be bio-individual and multifactorial.
Real progress is often seen in children with FRAs, but leucovorin does not address every aspect of autism. It may be helpful in managing specific symptoms, like speech or irritability, but cannot change the rest of the total load that contributes to the diagnosis.
Is Leucovorin Right for Your Child?
If you’re interested in learning more about whether leucovorin is right for your child, consider the following recommendations:
- Find a MAPS (Medical Academy of Pediatric Special Needs) doctor. This organization trains physicians on how to look for root causes and treat children with autism bio-individually.
- Have your child take a FRAT (Folate Receptor Antibody Test) to see whether your child is making antibodies to certain receptors in the brain that involve the usage of folate.
Why Individuals with Folate-Receptor Antibodies Should Avoid Dairy
One of the most important practical recommendations for individuals—especially children with autism—who have folate-receptor antibodies is to avoid dairy products. This is not simply a dietary preference, but a clinically backed strategy to improve the effectiveness of treatment and to minimize the activity of these antibodies.
Most forms of milk products consumed today contain a protein called folate receptor alpha. When dairy is consumed, this protein enters the body and—because it is structurally similar to human folate receptors—can trigger or worsen the immune response, causing the body to produce more antibodies against folate receptors. Eating or drinking dairy exposes the immune system to this foreign protein. For people already susceptible to FRAs, this additional exposure leads to increased production of the very antibodies that block folate transport into the brain. The result is a further decrease in available brain folate, worsening symptoms of cerebral folate deficiency.
Many specialists recommend a strict dairy-free diet for children with FRAs. This recommendation is based on evidence that avoiding dairy can help reduce antibody levels over time and improve response to treatments like leucovorin.
Parents who remove dairy from their child’s diet often see better outcomes, including improved behavior, communication, and responsiveness to folinic acid therapy.
In Conclusion
Leucovorin represents a remarkable advance for a subset of children with autism whose folate metabolism is disrupted by folate-receptor antibodies. By providing an activated form of folate, it can bypass obstacles at the cellular level and directly support neurological function. For those with this specific biological challenge, improvements may be both meaningful and profound. However, like any medical therapy, it is not universally effective nor entirely without risk.
Leucovorin’s selective benefit illustrates the importance of precision medicine—tailoring treatment to individual biology rather than a “one-size-fits-all” model. As awareness grows of folate-receptor antibodies’ impact on neurodevelopmental disorders, clinicians and families alike are better equipped to identify which children may gain from this intervention. Through careful screening, monitoring, and collaboration, leucovorin can offer hope and progress for many, while reinforcing the broader message that autism is a complex spectrum best addressed with empathy, science, and individualized care.
About Heather Tallman Ruhm MD
Heather Tallman Ruhm MD is the Medical Director of the Documenting Hope Project. She is a Board Certified Family Physician whose primary focus is whole-person health and patient education. She draws on her conventional western training along with insights and skills from functional, integrative, bioregulatory and energy medicine. She believes in the healing capacities of the human frame and supports the power of self-regulation to help her patients recover and access vitality.
About Maria Rickert Hong CHHC
Maria Rickert Hong is a Co-Founder of, and the Education and Media Director for, Documenting Hope.
She is a former sell-side Wall Street equity research analyst who covered the oil services sector at Salomon Smith Barney and Lehman Brothers under Institutional Investor #1 ranked analysts.
Later, she covered the gaming, lodging & leisure sector at Jefferies & Co. and Calyon Securities. She quit working on Wall Street when her first son was born.
Prior to working on Wall Street, she was a marketing specialist for Halliburton in New Orleans, where she also received her MBA in Finance & Strategy from Tulane University.
She is the author of the bestselling book Almost Autism: Recovering Children from Sensory Processing Disorder and the co-author of Brain Under Attack: A Resource for Parents and Caregivers of Children with PANS, PANDAS, and Autoimmune Encephalitis. She is a co-author of Reversal of Autism Symptoms among Dizygotic Twins through a Personalized Lifestyle and Environmental Modification Approach: A Case Report and Review of the Literature, J. Pers. Med. 2024, 14(6), 641.
Maria is also a Certified Holistic Health Counselor. Her work can be found on DocumentingHope.com, Healing.DocumentingHope.com, Conference.DocumentingHope.com and MariaRickertHong.com
Still Looking for Answers?
Visit the Documenting Hope Practitioner Directory to find a practitioner near you.
Join us inside our online membership community for parents, Healing Together, where you’ll find even more healing resources, expert guidance, and a community to support you every step of your child’s healing journey.
Sources & References
Elamin, N.E, et al. Brain autoantibodies in autism spectrum disorder. Biomark Med. 2014;8(3):345-52.
Frye, R.E., et al. Blocking and Binding Folate Receptor Alpha Autoantibodies Identify Novel Autism Spectrum Disorder Subgroups. Front Neurosci. 2016 Mar 9;10:80.
Frye, R.E., et al. Cerebral folate receptor autoantibodies in autism spectrum disorder. Mol Psychiatry. 2013 Mar;18(3):369-81.
Frye, R.E., et al. Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder. Semin Pediatr Neurol. 2020 Oct:35:100835.
Mader, S., et al. The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment. Front Immunol. 2017; 8: 1101.
Phunsawat, P., et al. Folate receptor alpha autoantibodies in children with autism spectrum disorder. Biomarkers. 2022 Dec;27(8):715-719.
Quadros, E.V., et al. Folate receptor autoantibodies are prevalent in children diagnosed with autism spectrum disorder, their normal siblings and parents. Autism Res. 2018 May;11(5):707-712.
Rossigonal, D.A., et al. Cerebral Folate Deficiency, Folate Receptor Alpha Autoantibodies and Leucovorin (Folinic Acid) Treatment in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis. J Pers Med. 2021 Nov 3;11(11):1141.
Wells, L., et al. Folate Receptor Alpha Autoantibodies in the Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) Population. J Pers Med. 2024 Jan 31;14(2):166.
Resources
Videos
Lambert, Beth. Leucovorin & Autism: What Parents Should Know (Part 2). YouTube. 23 Sep 2025.
Lynch, Ben. The Brain Folate Problem No One Is Explaining To Parents. YouTube. 5 Feb 2026.
